Scholars@Duke
construction release_alert
Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.
cancel

Phase III studies of brolucizumab versus aflibercept in nAMD: 48-week primary and key secondary outcomes from HAWK/HARRIER

Publication ,  Conference
Jaffe, GJ; Koh, AHC; Ogura, Y; Weichselberger, A; Holz, FG; Dugel, PU
Published in: INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
July 1, 2018
Link to item

Duke Scholars

Glenn Jay Jaffe
Author Glenn Jay Jaffe Ophthalmology, Vitreoretinal Diseases & Surgery

Published In

INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE

EISSN

1552-5783

ISSN

0146-0404

Publication Date

July 1, 2018

Volume

59

Issue

9

Location

Honolulu, HI

Publisher

ASSOC RESEARCH VISION OPHTHALMOLOGY INC

Conference Name

Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO)

Related Subject Headings

  • Ophthalmology & Optometry
  • 3212 Ophthalmology and optometry
  • 11 Medical and Health Sciences
  • 06 Biological Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Jaffe, G. J., Koh, A. H. C., Ogura, Y., Weichselberger, A., Holz, F. G., & Dugel, P. U. (2018). Phase III studies of brolucizumab versus aflibercept in nAMD: 48-week primary and key secondary outcomes from HAWK/HARRIER. In INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (Vol. 59). Honolulu, HI: ASSOC RESEARCH VISION OPHTHALMOLOGY INC.
Jaffe, Glenn J., Adrian H. C. Koh, Yuichiro Ogura, Andreas Weichselberger, Frank G. Holz, and Pravin U. Dugel. “Phase III studies of brolucizumab versus aflibercept in nAMD: 48-week primary and key secondary outcomes from HAWK/HARRIER.” In INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, Vol. 59. ASSOC RESEARCH VISION OPHTHALMOLOGY INC, 2018.
Jaffe GJ, Koh AHC, Ogura Y, Weichselberger A, Holz FG, Dugel PU. Phase III studies of brolucizumab versus aflibercept in nAMD: 48-week primary and key secondary outcomes from HAWK/HARRIER. In: INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE. ASSOC RESEARCH VISION OPHTHALMOLOGY INC; 2018.
Jaffe, Glenn J., et al. “Phase III studies of brolucizumab versus aflibercept in nAMD: 48-week primary and key secondary outcomes from HAWK/HARRIER.” INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, vol. 59, no. 9, ASSOC RESEARCH VISION OPHTHALMOLOGY INC, 2018.
Jaffe GJ, Koh AHC, Ogura Y, Weichselberger A, Holz FG, Dugel PU. Phase III studies of brolucizumab versus aflibercept in nAMD: 48-week primary and key secondary outcomes from HAWK/HARRIER. INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE. ASSOC RESEARCH VISION OPHTHALMOLOGY INC; 2018.

Published In

INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE

EISSN

1552-5783

ISSN

0146-0404

Publication Date

July 1, 2018

Volume

59

Issue

9

Location

Honolulu, HI

Publisher

ASSOC RESEARCH VISION OPHTHALMOLOGY INC

Conference Name

Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO)

Related Subject Headings

  • Ophthalmology & Optometry
  • 3212 Ophthalmology and optometry
  • 11 Medical and Health Sciences
  • 06 Biological Sciences